Cargando…

Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib

The multi-kinase inhibitor sorafenib is now used as standard therapy for advanced hepatocellular carcinoma (HCC). Predictive biomarkers of response to sorafenib are thus necessary. The purpose of this study was to assess the feasibility of using targeted DNA and RNA sequencing to elucidate candidate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakai, Kazuko, Takeda, Haruhiko, Nishijima, Norihiro, Orito, Etsuro, Joko, Kouji, Uchida, Yasushi, Izumi, Namiki, Nishio, Kazuto, Osaki, Yukio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673292/ https://www.ncbi.nlm.nih.gov/pubmed/26046304

Ejemplares similares

Sorafenib Therapy for BCLC Stage B/C Hepatocellular Carcinoma; Clinical Outcome and Safety in Aged Patients: A Multicenter Study in Japan
por: Nishikawa, Hiroki, et al.
Publicado: (2014)

Long‐term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion
por: Takeda, Haruhiko, et al.
Publicado: (2019)

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
por: Kobayashi, Masahiro, et al.
Publicado: (2019)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
por: Ko, Yi-Ling, et al.
Publicado: (2020)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Predictive factors in patients with hepatocellular carcinoma receiving sorafenib therapy using time-dependent receiver operating characteristic analysis
por: Nishikawa, Hiroki, et al.
Publicado: (2017)

Systematic evaluation and optimization of protein extraction parameters in diagnostic FFPE specimens
por: Dressler, Franz F., et al.
Publicado: (2022)

Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy
por: Sekiguchi, Shuhei, et al.
Publicado: (2022)

Two Cases of Hepatocellular Carcinoma Occurring Immediately after Direct-acting Antiviral Agents against Hepatitis C Virus
por: Nishijima, Norihiro, et al.
Publicado: (2018)

SimFFPE and FilterFFPE: improving structural variant calling in FFPE samples
por: Wei, Lanying, et al.
Publicado: (2021)

Sorafenib-induced acute interstitial pneumonia in patients with advanced hepatocellular carcinoma: report of three cases
por: Takeda, Haruhiko, et al.
Publicado: (2012)

The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study
por: Tsuchiya, Kaoru, et al.
Publicado: (2021)

Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma
por: Takada, Hitomi, et al.
Publicado: (2019)

A Non-Hazardous Deparaffinization Protocol Enables Quantitative Proteomics of Core Needle Biopsy-Sized Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue Specimens
por: Mitsa, Georgia, et al.
Publicado: (2022)

Sorafenib Combined with Cryoablation to Treat Unresectable Hepatocellular Carcinoma
por: Ni, Hong, et al.
Publicado: (2011)

Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Tsilimigras, Diamantis I., et al.
Publicado: (2020)

Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
por: Kudo, Masatoshi, et al.
Publicado: (2022)

REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
por: Yamashita, Tatsuya, et al.
Publicado: (2019)

Sorafenib Monotherapy in a Patient with Unresectable Hepatic Epithelioid Hemangioendothelioma
por: Kobayashi, Noritoshi, et al.
Publicado: (2016)

Complete Response to Sorafenib in Locally Recurrent Unresectable Aggressive Fibromatosis
por: Burney, Ikram A., et al.
Publicado: (2021)

High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens
por: Cheng, Lauren Y., et al.
Publicado: (2021)

Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma
por: Nojiri, Shunsuke, et al.
Publicado: (2012)

Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma
por: NISHIKAWA, HIROKI, et al.
Publicado: (2012)

Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma
por: Arizumi, Tadaaki, et al.
Publicado: (2014)

Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON
por: Kudo, Masatoshi, et al.
Publicado: (2016)

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
por: Wang, Wan, et al.
Publicado: (2019)

Application of Amplicon-Based Targeted NGS Technology for Diagnosis of Drug-Resistant Tuberculosis Using FFPE Specimens
por: Song, Jing, et al.
Publicado: (2022)

Detection of high-risk HPV in FFPE specimens of various tumours using the BD Onclarity™ HPV Assay
por: van der Geize, Robert, et al.
Publicado: (2022)

Digital multiplexed analysis of circular RNAs in FFPE and fresh non‐small cell lung cancer specimens
por: Pedraz‐Valdunciel, Carlos, et al.
Publicado: (2022)

Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
por: Leung, Henry W. C., et al.
Publicado: (2016)

Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma
por: Takano, Michitoshi, et al.
Publicado: (2016)

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer
por: Danilovic, Debora L. S., et al.
Publicado: (2018)

Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients
por: Nishikawa, Hiroki, et al.
Publicado: (2014)

Prognostic factors in patients with hepatitis B virus-related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy
por: NISHIKAWA, HIROKI, et al.
Publicado: (2013)

Optimal treatment for castration-resistant prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2014)

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma
por: Mahvash, Armeen, et al.
Publicado: (2016)

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs
por: Marconato, Laura, et al.
Publicado: (2020)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma
por: Huang, Kuo-Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8kkulrcs6pd87tpp1gulu28umj